2017 American Transplant Congress
Plasma Cell Hepatitis in Primary Sclerosing Cholangitis Patients: 15-Year Experience at a Transplant Center.
Background: Plasma cell hepatitis (PCH) is an uncommon liver graft dysfunction which occurs in liver transplant (LT) recipients of different etiologies other than autoimmune hepatitis.…2016 American Transplant Congress
Tumor-Necrosis-Factor-α Antagonist Therapy for Inflammatory Bowel Disease After Liver Transplantation.
Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI.
Background:The safety and effectiveness of tumor-necrosis-factor-α antagonist (anti-TNF-α) therapy for inflammatory bowel disease (IBD) has not been well-established in patients after liver transplantation (LT). We…2015 American Transplant Congress
Early Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation Has No Negative Impact on Patients outcome'
Liver transplantation (LT) is the only therapeutic option for primary sclerosing cholangitis (PSC), however, recurrence of PSC (rPSC) post-LT occurs at rates ranging from 9-47%.…
American Transplant Congress abstracts